<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787891</url>
  </required_header>
  <id_info>
    <org_study_id>CR014833</org_study_id>
    <secondary_id>RABGRD3003</secondary_id>
    <nct_id>NCT00787891</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients</brief_title>
  <official_title>A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endoscopically Proven GERD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the
      treatment of acid-related disorders in pediatric patients, focusing specifically on the
      manifestation of GERD (symptomatic and erosive types).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind study that consists of two parts. In Part 1, the study
      will consist of 3 phases: a 14-day screening phase, a double-blind treatment phase of 12
      weeks comparing two doses of study drug (0.5 mg/kg or 1.0 mg/kg groups based on patient's
      body weight), and an end-of-study or early withdrawal phase followed by Part 2, which
      consists a of double-blind treatment continuation for patients who have achieved healing
      during the short-term double-blind treatment phase. The double-blind maintenance treatment
      phase lasts for not more than 24 weeks and is concluded by an end-of-study/early withdrawal
      visit. During Part 1, patients will be screened and the diagnosis of erosive and non-erosive
      Gastroesophageal Reflux Disease (GERD) will be made based on clinical symptoms and confirmed
      by endoscopy/histology after a biopsy. Patients enrolled in the study will receive study drug
      once daily for 12 weeks. Each day, the parent/caregiver will record the presence and severity
      of pre-specified GERD symptoms. At Weeks 4 and 8, the investigator will evaluate the response
      to treatment by assessment of the GERD symptoms. At Week 12, the investigator will perform an
      endoscopy of the esophagus with a biopsy to confirm that histological healing has occurred.
      If a patient continues, additional study drug will be dispensed (at the same dose taken
      during the short-term double-blind treatment phase) and the patient will be scheduled to
      return every 8 weeks until study drug is discontinued at Week 24 (Part 2) of the double-blind
      maintenance treatment phase. At the final visit of the maintenance treatment phase Week 24
      (Part 2), assessments including an endoscopy of the esophagus with a biopsy be performed for
      each patient. Assessments of effectiveness include endoscopic and histological grading of
      biopsy samples, GERD symptom and severity score (symptoms and severity rated daily by the
      parent/caregiver in an electronic diary), overall GERD symptom relief, Clinical Global
      Impression of Improvement (CGI-I) score, and the Global Treatment Satisfaction Score. Safety
      assessments will include the monitoring of concomitant therapies and adverse events
      throughout the study, clinical laboratory testing (including hematology, clinical chemistry,
      urinalysis), vital signs, and physical examination including height, weight, and Tanner
      staging. Oral rabeprazole 2.5 capsules or 5 mg capsules, given once daily at a dose of 0.5
      mg/kg or 1.0 mg/kg; short-term treatment phase is 12 weeks; long-term maintenance treatment
      phase is 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Gastroesophageal Reflux Disease (GERD)</condition>
  <arm_group>
    <arm_group_label>Rabeprazole 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabeprazole 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabeprazole</intervention_name>
    <description>0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks</description>
    <arm_group_label>Rabeprazole 0.5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabeprazole</intervention_name>
    <description>1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks</description>
    <arm_group_label>Rabeprazole 1.0 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of at least 1 Gastroesophageal Reflux Disease (GERD) symptom within 3 months
             of screening

          -  Positive esophagogastroduodenoscopy

          -  Signed informed consent

          -  Female patients (if menstruating) must be practicing birth control

        Exclusion Criteria:

          -  Patients with history of esophagitis

          -  Patients who have milk protein allergy

          -  Patients who have taken Proton Pump Inhibitors or H2-blockers within 3 days

          -  Patients who have taken sucralate or any medication that affects gastrointestinal
             motility

          -  Patients with H. pylori

          -  Patients with lab values outside the normal age appropriate range

          -  Patients who have participated in another trial within 30 days before screening

          -  Patients with allergies to Proton Pump Inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <results_first_submitted>July 27, 2012</results_first_submitted>
  <results_first_submitted_qc>September 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2012</results_first_posted>
  <disposition_first_submitted>July 6, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 6, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 18, 2012</disposition_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroesophageal Reflux Disease (GERD)</keyword>
  <keyword>Erosive Gastroesophageal Reflux Disease</keyword>
  <keyword>Ulcerative Gastroesophageal Reflux Disease</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Rabeprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In this study, 108 patients completed the 12-week phase (Part 1) and were counted for the primary outcome measure (OM). Patients with healing at Week 12 had the option to continue the treatment for 24 weeks. Among the 87 with healing, 64 enrolled into Part 2. Only 52 had the primary efficacy endpoint available and were included in the primary OM.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rabeprazole 0.5 mg/kg</title>
          <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
        </group>
        <group group_id="P2">
          <title>Rabeprazole 1.0 mg/kg</title>
          <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Short-term Double-blind Phase (Part 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Double-blind Phase (Part 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rabeprazole 0.5 mg/kg</title>
          <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
        </group>
        <group group_id="B2">
          <title>Rabeprazole 1.0 mg/kg</title>
          <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="3.49"/>
                    <measurement group_id="B2" value="5.4" spread="3.26"/>
                    <measurement group_id="B3" value="5.7" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline BMI</title>
          <units>kg/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.5" spread="4.08"/>
                    <measurement group_id="B2" value="16.8" spread="3.11"/>
                    <measurement group_id="B3" value="17.2" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)</title>
        <description>Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention to Treat (ITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole Sodium 0.5 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
          <group group_id="O2">
            <title>Rabeprazole Sodium 1.0 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)</title>
          <description>Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.</description>
          <population>Intention to Treat (ITT) analysis set</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="67" upper_limit="89"/>
                    <measurement group_id="O2" value="83" lower_limit="73" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)</title>
        <description>Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.</description>
        <time_frame>36 weeks</time_frame>
        <population>Intention to Treat (ITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole Sodium 0.5 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
          <group group_id="O2">
            <title>Rabeprazole Sodium 1.0 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)</title>
          <description>Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.</description>
          <population>Intention to Treat (ITT) analysis set</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O2" value="88" lower_limit="76" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)</title>
        <description>The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intention to Treat (ITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole Sodium 0.5 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
          <group group_id="O2">
            <title>Rabeprazole Sodium 1.0 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)</title>
          <description>The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.</description>
          <population>Intention to Treat (ITT) analysis set</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.85"/>
                    <measurement group_id="O2" value="-1.0" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)</title>
        <description>The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intention to Treat (ITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole Sodium 0.5 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
          <group group_id="O2">
            <title>Rabeprazole Sodium 1.0 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)</title>
          <description>The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.</description>
          <population>Intention to Treat (ITT) analysis set</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="11.70"/>
                    <measurement group_id="O2" value="-8.5" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)</title>
        <description>The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention to Treat (ITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole Sodium 0.5 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
          <group group_id="O2">
            <title>Rabeprazole Sodium 1.0 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)</title>
          <description>The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.</description>
          <population>Intention to Treat (ITT) analysis set</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.49"/>
                    <measurement group_id="O2" value="0.2" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)</title>
        <description>The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>Intention to Treat (ITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole Sodium 0.5 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
          <group group_id="O2">
            <title>Rabeprazole Sodium 1.0 mg/kg</title>
            <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)</title>
          <description>The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.</description>
          <population>Intention to Treat (ITT) analysis set</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="4.82"/>
                    <measurement group_id="O2" value="-1.4" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rabeprazole 0.5 mg/kg (Short-term Double-blinde Phase)</title>
          <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
        </group>
        <group group_id="E2">
          <title>Rabeprazole 1.0 mg/kg (Short-term Double-blinde Phase)</title>
          <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
        </group>
        <group group_id="E3">
          <title>Rabeprazole 0.5 mg/kg (Double-blind Maintenance Phase)</title>
          <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
        </group>
        <group group_id="E4">
          <title>Rabeprazole 1.0 mg/kg (Double-blind Maintenance Phase</title>
          <description>Pediatric micro-bead formulation of rabeprazole sodium orally administered.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Partial Seizures with Secondary Generalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Conversion Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Eustachian Tube Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tympanic Membrane Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Eosinophilic Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Irritable Bowel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Atopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Croup Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Coxsackie Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Molluscum Contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fungal Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash Pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Arthropod Sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Procedural Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ulna Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Body Temperature Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Beta 2 Microglobulin Urine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Iron Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Serum Ferritin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Iron Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Mental Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Breast Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Adenoidal Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Asthma Exercise Induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Increased Upper Airway Secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pharyngeal Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Postnasal Drip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bronchial Hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Skin Exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dermatitis Diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Menarche</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Suture Insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tooth Extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>PORTFOLIO/CDT LEADER</name_or_title>
      <organization>Janssen R&amp;D US</organization>
      <phone>1 609 730-2548</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

